Tags

Type your tag names separated by a space and hit enter

A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Am J Trop Med Hyg. 2007 Oct; 77(4):640-6.AJ

Abstract

Azithromycin was compared with meglumine antimoniate for treatment of patients with cutaneous leishmaniasis. Patients were randomized to receive oral azithromycin, 500 mg/day (22 patients) or intramuscular meglumine antimoniate, 10 mg Sb/kg/day (23 patients), both for 28 days, with a second cycle of 15 days if necessary, and followed-up for one year after completion of treatment. Efficacy, defined as complete re-epithelization without relapse for 12 months after completing therapy, was 82.6% (95% confidence interval [CI] = 67-98%) for meglumine antimoniate and 45.5% (95% CI = 25-66%) for azithromycin. All patients who failed treatment with azithromycin were treated with meglumine antimoniate and clinically cured. Azithromycin was well tolerated; meglumine antimoniate caused arthralgias and local symptoms in 78% of the patients. In 17 cases, species identification was obtained; Leishmania (Viannia) braziliensis was identified in all of them. For the treatment of American cutaneous leishmaniasis caused by L. (V.) braziliensis, meglumine antimoniate is significatively more efficacious than azithromycin, which was clinically curative in almost half of the patients and well-tolerated.

Authors+Show Affiliations

Instituto de Investigaciones en Enfermedades Tropicales, Universidad Nacional de Salta, Sede Regional Orán, San Ramón de la Nueva Orán, Salta, Argentina. alekro@huesped.org.arNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17978064

Citation

Krolewiecki, Alejandro J., et al. "A Randomized Clinical Trial Comparing Oral Azithromycin and Meglumine Antimoniate for the Treatment of American Cutaneous Leishmaniasis Caused By Leishmania (Viannia) Braziliensis." The American Journal of Tropical Medicine and Hygiene, vol. 77, no. 4, 2007, pp. 640-6.
Krolewiecki AJ, Romero HD, Cajal SP, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg. 2007;77(4):640-6.
Krolewiecki, A. J., Romero, H. D., Cajal, S. P., Abraham, D., Mimori, T., Matsumoto, T., Juarez, M., & Taranto, N. J. (2007). A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. The American Journal of Tropical Medicine and Hygiene, 77(4), 640-6.
Krolewiecki AJ, et al. A Randomized Clinical Trial Comparing Oral Azithromycin and Meglumine Antimoniate for the Treatment of American Cutaneous Leishmaniasis Caused By Leishmania (Viannia) Braziliensis. Am J Trop Med Hyg. 2007;77(4):640-6. PubMed PMID: 17978064.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. AU - Krolewiecki,Alejandro J, AU - Romero,Héctor D, AU - Cajal,Silvana P, AU - Abraham,David, AU - Mimori,Tatsuyuki, AU - Matsumoto,Tamami, AU - Juarez,Marisa, AU - Taranto,Nestor J, PY - 2007/11/6/pubmed PY - 2007/12/12/medline PY - 2007/11/6/entrez SP - 640 EP - 6 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 77 IS - 4 N2 - Azithromycin was compared with meglumine antimoniate for treatment of patients with cutaneous leishmaniasis. Patients were randomized to receive oral azithromycin, 500 mg/day (22 patients) or intramuscular meglumine antimoniate, 10 mg Sb/kg/day (23 patients), both for 28 days, with a second cycle of 15 days if necessary, and followed-up for one year after completion of treatment. Efficacy, defined as complete re-epithelization without relapse for 12 months after completing therapy, was 82.6% (95% confidence interval [CI] = 67-98%) for meglumine antimoniate and 45.5% (95% CI = 25-66%) for azithromycin. All patients who failed treatment with azithromycin were treated with meglumine antimoniate and clinically cured. Azithromycin was well tolerated; meglumine antimoniate caused arthralgias and local symptoms in 78% of the patients. In 17 cases, species identification was obtained; Leishmania (Viannia) braziliensis was identified in all of them. For the treatment of American cutaneous leishmaniasis caused by L. (V.) braziliensis, meglumine antimoniate is significatively more efficacious than azithromycin, which was clinically curative in almost half of the patients and well-tolerated. SN - 0002-9637 UR - https://www.unboundmedicine.com/medline/citation/17978064/A_randomized_clinical_trial_comparing_oral_azithromycin_and_meglumine_antimoniate_for_the_treatment_of_American_cutaneous_leishmaniasis_caused_by_Leishmania__Viannia__braziliensis_ L2 - http://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -